SAN DIEGO, July 15 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will Webcast its Quarterly Update Conference Call for the
second quarter of 2008 on Monday, July 21, 2008 at 5:00 p.m. ET/2:00 p.m. PT.
Daniel M. Bradbury, Amylin's President and Chief Executive Officer, will lead
the call. On the same date post-market, Amylin will release financial results
for the second quarter of 2008.
The call will be Webcast live through Amylin's corporate Web site and a
recording will be made available following the close of the call. To access
the Webcast, please log on to http://www.amylin.com approximately fifteen
minutes prior to the call to register, download and install any necessary
audio software. For those without access to the Internet, the live call may be
accessed by phone by calling (866) 244-4530 (U.S./Canada) or (703) 639-1173
(international), Conference ID# 1262019. A replay of the call will also be
available by phone beginning approximately two hours after the close of the
call and can be accessed at (888) 266-2081 (U.S./Canada) or (703) 925-2533
(international), Conference ID# 1262019.
About Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. is a biopharmaceutical company committed to
improving lives through the discovery, development and commercialization of
innovative medicines. Amylin has developed and gained approval for two
first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate)
injection and BYETTA(R) (exenatide) injection. Amylin's research and
development activities leverage the company's expertise in metabolism to
develop potential therapies to treat diabetes and obesity. Amylin is located
in San Diego, California with over 2,000 employees nationwide. Further
information on Amylin Pharmaceuticals is available at http://www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.
